Summary
Tiziana Life Sciences doses first patient in mid-stage Alzheimer's trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Wednesday it has dosed the first patient in a Phase 2 clinical trial testing its intranasal drug candidate foralumab in patients with early Alzheimer's disease. The randomized, placebo-controlled study will evaluate foralumab as a standalone treatment and in combination with FDA-approved anti-amyloid drugs lecanemab (Leqembi) or donanemab in people with early or mild Alzheimer's, the company said.
Tiziana Life Sciences to begin patient dosing in Phase 2 Alzheimer's trial next week
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has begun enrolling participants in its Phase 2 randomized, placebo-controlled clinical trial evaluating intranasal foralumab in early Alzheimer's disease, with the first patient expected to be dosed next week. The trial will study foralumab, a fully human anti-CD3 monoclonal antibody, as both a standalone therapy and in combination with the FDA-approved anti-amyloid drugs lecanemab or donanemab.
Tiziana Life Sciences plans spinout of IL-6 antibody program
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday it plans to spin out its anti-IL-6 receptor antibody program, TZLS-501, into a separately listed public company. Tiziana said its decision follows rising industry interest in the IL-6 pathway, highlighted by Novartis' $1.4 billion acquisition of Tourmaline Bio and its IL-6 inhibitor pacibekitug.
Tiziana Life Sciences Ltd. (TLSA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tiziana Life Sciences Ltd. ever had a stock split?
Tiziana Life Sciences Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Ivor R. Elrifi CEO | NASDAQ (CM) Exchange | 88875G101 CUSIP |
| GB Country | 9 Employees | - Last Dividend | 31 Jul 2020 Last Split | 24 Mar 2000 IPO Date |
Overview
Tiziana Life Sciences Ltd is a biotechnology firm based in London, the United Kingdom, established in 1998. The company is dedicated to discovering and developing innovative molecules aimed at treating human diseases, with a primary focus on oncology and immunology. Leveraging advanced biotechnological methodologies, Tiziana Life Sciences is poised to address some of the most challenging medical conditions by advancing its research in monoclonal antibodies and small molecule inhibitors.
Products and Services
Foralumab (TZLS-401): Positioned as the company's forefront candidate in immunology, Foralumab is a groundbreaking human anti-CD3 monoclonal antibody (mAb). This therapeutic agent is being explored for its potential to treat a variety of autoimmune and inflammatory diseases, including Crohn's disease, graft-versus-host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. By targeting the CD3 antigen on T-lymphocytes, Foralumab is designed to modulate immune responses, offering hope for patients suffering from these chronic conditions.
Milciclib (TZLS-201): Milciclib represents another significant facet of Tiziana's developmental portfolio. As a small molecule inhibitor, Milciclib targets a range of cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases. These kinases are pivotal in the regulation of cell growth and the malignant progression of cancer. Through the inhibition of these kinases, Milciclib has the potential to stop cancer cells from growing and dividing uncontrollably, offering a strategic approach to cancer treatment.
Anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501): This fully human monoclonal antibody is designed to block the interleukin 6 (IL6) pathway, a critical mediator of inflammation and a known contributor to autoimmune diseases and cytokine release syndrome. By targeting IL6-induced inflammation, the anti-IL6R mAb presents a promising treatment avenue for conditions driven by excessive inflammation. Additionally, its application in treating COVID-19 patients by mitigating the severe respiratory symptoms associated with the virus demonstrates the versatility and potential impact of Tiziana's research in addressing urgent global health challenges.
